Episode 33 · January 30, 2026 · 30m listen · 3,975 words · ~20 min read

The Hidden Reason Medtech Products Get Recalled (It's Not Quality Issues) with William Jin | Ep. 55 - Full Transcript | The Med Device Cyber Podcast

Read the complete, searchable transcript of Episode 33 of The Med Device Cyber Podcast - expert conversations on medical device cybersecurity, FDA premarket and postmarket guidance, SBOM management, threat modeling, and penetration testing.

Prefer the listening experience? Open the episode page for the synopsis, key takeaways, topics, and Apple / YouTube listen links.

Episode summary

In this episode of the Med Device Cyber Podcast, hosts Trevor Slattery and Christian Espinosa are joined by special guest William Jin, a seasoned expert with over 30 years of experience in the medical technology industry. With a background as a medical doctor in Shanghai and extensive work with major companies like Medtronic and Stryker, Mr. Jin now specializes in bridging the gap between the Chinese and international MedTech markets. The discussion centers on the complexities and opportunities of navigating the world's two largest medical markets: the United States and China. The episode opens by highlighting the phenomenal growth of the Chinese market, which has rapidly become the second-largest globally and shows no signs of slowing down. This growth presents a significant opportunity for both international firms looking to enter China and for Chinese companies aiming for global expansion. Mr. Jin provides a nuanced perspective on the challenges faced from both directions. He observes that many of the 1.5 million MedTech companies in China are not yet prepared for the rigorous demands of US or European markets, citing gaps in regulatory knowledge, intellectual property strategy, and cybersecurity preparedness. Conversely, he details the significant hurdles for Western companies entering China. A primary argument is the necessity of planning for target markets from the very beginning of the product development lifecycle. Critical design choices made early on, such as selecting a cloud platform, can have massive downstream consequences. For example, a device built on Google's cloud platform is entirely unviable in China, where Google is banned, necessitating a costly and time-consuming redesign on an approved platform like Alibaba Cloud or a China-based Amazon server. The conversation also emphasizes the increasing importance of cybersecurity, not as a feature to be added later, but as a foundational element from "design to disposal." With evolving regulations, strict data sovereignty laws in China, and the rising number of product recalls due to cybersecurity flaws, the hosts and guest conclude that a proactive, market-specific cybersecurity strategy is no longer optional but essential for success in the global MedTech landscape.

Key takeaways from this episode

The Chinese medical market is the second largest in the world and continues to expand, but presents unique regulatory and technical challenges for market entry.
Many Chinese MedTech companies are not fully prepared for the regulatory, IP, and cybersecurity standards required to successfully enter the US and European markets.
Cybersecurity must be integrated into the entire product lifecycle, from initial design to disposal, to avoid costly redesigns, regulatory rejections, and product recalls.
Companies aiming for global sales must reverse engineer their product, considering the specific requirements of each target market, especially concerning data handling and cloud infrastructure.
US companies entering China face significant data-related hurdles; platforms like Google are prohibited, and strict laws govern cross-border patient data transfer, often requiring a separate product version.
Choosing a cloud provider is a critical early-stage decision that can determine a product's viability in certain international markets like China.
Chinese exports of medical products to North America have seen a slight decrease, while exports to Europe are increasing, indicating shifting global market dynamics.
Both US and Chinese startups need to establish a clear global market strategy early in development to avoid creating a product that is unsellable in valuable markets.

Full episode transcript

Host: You don't want to spend all of this time, spend all of this money creating a product you're not actually going to be able to sell in really valuable markets for you. Guest: There are 1.5 million companies in China. Host: The Chinese market very quickly moved its way up to the second largest medical market in the world, and it is showing no signs of slowing down. Guest: When I'm talking to a lot of Chinese companies in MedTech areas, I get the feeling that a lot of company, they are not ready to get to a US market or a European market. Host: We always say cybersecurity should be considered from design to disposal of the product, the entire lifecycle. Host: Hello and welcome back to the MedDevice Cyber Podcast. I'm your co-host Trevor Slattery, joined with our other co-host Christian Espinosa. Host: And today, we have a very special guest, William Jin. We're going to dive in to talking about some of our typical North Star with cybersecurity and then looking a little bit into some of these differences that we see between the US market as well as the Chinese market. Now, before we dive in too far, I'll turn it over to you, William, to give a little bit of an introduction of yourself, a bit of background, and then we can jump right in. Guest: Yeah, I was educated uh as a medical doctor in Shanghai, China. And then I'm moving in the industry like more than 30 years. I worked for a company like Medtronic and Stryker. So, right now, I'm pretty much focused on helping the uh overseas, outside of China MedTech company, especially innovative product into China market, as well as support the uh Chinese MedTech companies if they are willing to go abroad. Host: Awesome. So you're helping uh kind of both directions. Chinese companies trying to get to uh United States as an example and US companies trying to get in the Chinese market. It's, is that correct? Guest: Yes, yes. I start with helping the overseas getting into China market, but now there are more and more Chinese company they are finding the way to go to US and uh European market. But I find uh a data, latest data from the uh China statistic data, the Chinese export to Europe and US, the data actually to North America is decreased in year 2000, 2025 versus 24. Decreased like a 5%. But to Europe like uh increased like 11%. So uh, that's uh seems uh although overall Chinese company MedTech, they want to go abroad, but seems it's not uh reflect in the numbers to North America. Host: Lines up with the uh the new tariffs coming in on just about everything imported to the US, so I can't say I'm surprised to hear that. Guest: Yeah, I I think this is one of the reason, the tariff. But I still when I'm talking to a lot of Chinese companies in MedTech areas, I get a feeling that a lot of company, they are not ready to get to a US market or European market. I think uh not only on the IP perspective, I think that's the uh, you know, always the issues about IPs and and also uh uh coupled with uh the commercial knowledge, how to launch your product into another market, especially in a more mature market. And uh how you, do you have a talent, do you have a knowledge? But right now, like our discussion, I think uh a lot of MedTech product is getting to like wireless, getting to iCloud, getting to uh data, you know, algorithm, then it's uh, I talked to the company, most of them they are not ready or fully aware about the cybersecurity and what kind of requirement in uh outside of China. So I think uh all these are the uh barriers or the uh challenges for a Chinese company, MedTech company if they are plan to go US or Europe. Host: And what are some of the challenges with a, let's say, US, United States based company going into China? What are some of the main challenges you see on uh that angle? Guest: From US to China, right? On the MedTech side, I think uh the normal factors will be like you understand the local market, you have a local talent, and also the registration time is much longer than in US and Europe. It takes like three to five years based on your categories, three or two or three. Most recently, I feel, I have uh two cases about the datas. Because for example, you know, some of a MedTech product, they are developed under Google platform. So all the other associate they are build up on a Google platform. But Google platform is not allowed in China market. It's not allowed by the Chinese government.

1 / 5